Innate and adaptive nasal mucosal immune responses following experimental human pneumococcal colonization

Simon P. Jochems, … , Maria Yazdanbakhsh, Daniela M. Ferreira

Research | In-Press Preview | Immunology | Infectious disease

Graphical abstract

□

Find the latest version:

http://jci.me/128865/pdf

Innate and adaptive nasal mucosal immune responses following experimental human pneumococcal colonization

Simon P. Jochems[1,2,*], Karin de Ruiter[2,*], Carla Solórzano[1,*], Astrid Voskamp[2,*], Elena Mitsi[1], Elissavet Nikolaou[1], Beatriz F Carniel[1], Sherin Pojar[1], Esther L. German[1], Jesús Reiné[1], Alessandra Soares-Schanoski[3], Helen Hill[1,4], Rachel Robinson[1,4], Angela D. Hyder-Wright[1,4], Caroline M. Weight[5], Pascal F. Durrenberger[6], Robert S. Heyderman[5], Stephen B. Gordon[1,7], Hermelijn H. Smits[2], Britta C. Urban[8], Jamie Rylance[1], Andrea M. Collins[1,4,9], Mark D. Wilkie[4], Lepa Lazarova[1,4], Samuel C. Leong[1,10], Maria Yazdanbakhsh[2,#], Daniela M. Ferreira[1,#]

[1] Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom
[2] Department of Parasitology, Leiden University Medical Center, Leiden, Netherlands
[3] Bacteriology Laboratory, Butantan Institute, Sao Paulo, Brazil
[4] Royal Liverpool and Broadgreen University Hospital, Liverpool, United Kingdom
[5] Division of Infection and Immunity, University College London, London, United Kingdom
[6] Centre for Inflammation and Tissue Repair, University College London, London, United Kingdom
[7] Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi
[8] Department of Parasitology, Liverpool School of Tropical Medicine, Liverpool, United Kingdom
[9] Aintree University Hospital NHS Foundation Trust, Liverpool, United Kingdom
[10] Department of Otorhinolaryngology – Head and Neck Surgery, Aintree University Hospital NHS Foundation Trust, Liverpool, United Kingdom
[*] Joint first authors
[#] Joint senior authors

Corresponding authors: Simon Jochems (Albinusdreef 2, 2333 ZA, Leiden, Netherlands; +31(0)715261404; s.p.jochems@lumc.nl) and Daniela Ferreira (Pembroke Place, L3 5QA, Liverpool, UK; +44 (0)1517053711; daniela.ferreira@lstmed.ac.uk).

The authors have declared that no conflict of interest exists.

Abstract

Streptococcus pneumoniae (Spn) is a common cause of respiratory infection, but also frequently colonizes the nasopharynx in the absence of disease. We used mass cytometry to study immune cells from nasal biopsy samples collected following experimental human pneumococcal challenge in order to identify immunological mechanisms of control of Spn colonization. Using 37 markers, we characterized 293 nasal immune cell clusters, of which 7 were associated with Spn colonization. B cell and CD8[+]CD161[+] T cell clusters were significantly lower in colonized than in non-colonized subjects. By following a second cohort before and after pneumococcal challenge we observed that B cells were depleted from the nasal mucosa upon Spn colonization. This associated with an expansion of Spn polysaccharide-specific and total plasmablasts in blood. Moreover, increased responses of blood mucosal associated invariant T (MAIT) cells against *in vitro* stimulation with pneumococcus prior to challenge associated with protection against establishment of Spn colonization and with increased mucosal MAIT cell populations. These results implicate MAIT cells in the protection against pneumococcal colonization and demonstrate that colonization affects mucosal and circulating B cell populations.

Introduction

Streptococcus pneumoniae (Spn) is a major cause of morbidity and mortality worldwide (1, 2). It is the most common bacterial cause of otitis media, pneumonia and meningitis in children (1). Risk factors for pneumococcal disease include very young or advanced age, co-infection with influenza, HIV infection, chronic lung disease, asplenia and smoking (3).

However, nasopharyngeal colonization, or carriage, of Spn in the absence of disease is common, with approximately 50% of infants and 10% of adults colonized at any time (4). Carriage is an immunising event in both children and adults but is also important as a prerequisite of disease and as the source of transmission (5-8). Successful colonization by Spn depends on many factors including bacterial factors, niche competition with other microbes, evasion of mucociliary clearance and host nutrient availability as well as immunological control of Spn (9). Epidemiological and modelling data have demonstrated that the immunizing effect of carriage is likely mediated by a combination of serotype-dependent and serotype-independent mechanisms (10-12).

The introduction of pneumococcal conjugate vaccines (PCV) has led to significant reductions in carriage prevalence of covered serotypes, leading to herd protection and a decrease in pneumococcal disease in unvaccinated adults in addition to conferring direct protection (13). However, only 13 of approximately 100 Spn serotypes are currently covered by PCVs and the elucidation of immune mechanisms that associate with the control of Spn carriage remains an area of active investigation (14).

Mouse models have suggested that Th17-mediated recruitment of neutrophils and monocytes to the nasopharynx is the mechanism of control and clearance of Spn carriage (15-17). In contrast, depletion of B cells or CD8[+] T cells did not impair the clearance of Spn in murine models (18, 19). Amplification of monocyte recruitment in an auto-feedback loop via CCL2 was found to be important for clearance, further supporting the role for these cells in control of carriage (20). Innate factors have also been implicated in murine models as disruption of IFN-α or interleukin-1 signalling is

3

71   associated with increased colonization (21, 22). Recently, we demonstrated using an experimental

72   human pneumococcal challenge (EHPC) model that carriage leads to degranulation of nasal-

73   resident neutrophils and recruitment of monocytes to the nasal mucosal surface (23). These

74   responses were impaired by co-infection with live attenuated influenza virus, which associated with

75   increased carriage density (24). Protection against experimental carriage acquisition in an

76   unvaccinated setting is further associated with the levels of circulating memory B cells, but not levels

77   of IgG, directed against the Spn polysaccharide capsule (25). Following PCV, very high levels of IgG

78   associate with protection against experimental carriage acquisition, likely by mediating Spn

79   agglutination followed by mucociliary clearance (26, 27). However, the relative role of these and

80   other adaptive and innate immune cell subsets in controlling Spn at the human nasal mucosa

81   remains largely unknown (28). The relatively small number of cells that can be collected from the

82   nasal mucosa using minimally-invasive nasal curettage has limited the capacity to analyse the role

83   of cellular subsets in controlling Spn carriage at the human nasal mucosa (29).

84   Here, we collected nasal biopsies under local anaesthesia following experimental human

85   pneumococcal challenge. This allowed for a comprehensive analysis of mucosal immunity during

86   Spn carriage as these samples yield substantially more cells than minimally-invasive curettes. Nasal

87   mucosal samples were analysed using mass cytometry (CyTOF), a technique in which antibodies

88   are labelled with rare earth metals and that enabled the investigation of 37 protein markers

89   simultaneously on a single-cell level (30). This method is ideally suited to investigate the relative

90   understudied mucosal immune populations as the large number of markers allow the identification

91   of previously unknown cell subsets and markers. Indeed, CyTOF has recently provided new insights

92   into alveolar macrophage subpopulations in the lung and innate lymphoid cells differentiation

93   pathways in the gut (31, 32). By combining nasal biopsies and CyTOF, we were thus able to study

94   in-depth the immunological role of innate and adaptive cell subsets at the human nasal mucosa and

95   their role during pneumococcal colonization.

96

Results

Characterization of nasal immune populations

Twenty healthy subjects negative for natural pneumococcal carriage at baseline screening were challenged intranasally with type 6B Spn (Figure 1A and Table 1). Carriage state was assessed at days two and seven post challenge and a nasal biopsy was collected at ten days post challenge (Supplementary Video 1), the timepoint at which Spn starts to be cleared from the nose (33, 34). Eight subjects became colonized with Spn (carriage$^+$), while twelve subjects remained carriage$^-$ (Figure 1A). Biopsies yielded a median of 2.3×10^5 cells (IQR: 1.6×10^5 - 3.2×10^5) per subject, approximately 90% of which were stromal cells, which were stained with a panel of thirty-eight antibodies and analysed by CyTOF (Figure 1B, Supplementary Table 1). Viable immune cells were manually gated from all acquired events and subsequently clustered by hierarchical-stochastic neighbour embedding (h-sne) using Cytosplore software (Figure 1C,2) (35-37). H-sne is a recently developed method in which t-distributed stochastic neighbor embedding (t-sne) is performed sequentially to cluster first global cell populations, each of which is then in turn clustered into subpopulations.

Based on the expression of 37 markers, a total of 199,426 immune cells from all subjects were divided into nine lineages (CD8$^+$ T cells, CD4$^+$ T cells, myeloid cells, innate lymphoid cells, B cells, double-negative T cells, granulocytes, CD117$^+$ cells and plasma cells, in order of decreasing abundance). These cell lineages were further divided into twenty-two subpopulations and 293 clusters (Figure 1C and Table 2). Cell numbers were normalized to the number of stromal cells for each subject to correct for varying biopsy yields. Normalized abundancies were then compared between carriage$^-$ and carriage$^+$ subjects for each of the lineages, subpopulations and clusters. There were no significant differences in frequencies between total lineages or subpopulations between carriage$^-$ and carriage$^+$ subjects. However, at a finer level seven clusters were significantly higher in carriage$^-$ than in carriage$^+$ subjects (Figure 1C, blue bars). Of note, three B cell clusters were higher in carriage$^-$ subjects (Figure 1C). Moreover, three CD8$^+$ T cell clusters, all expressing

123 CD161, and one CD8^{dim} T cell cluster were higher in carriage$^-$ subjects than in carriage$^+$ subjects

124 (Figure 1C). The seven significant clusters strongly correlated (r>0.70) with eighty-eight clusters in

125 other lineages/subpopulations, sixty-eight of which were in B or T cell lineages, highlighting an

126 interconnectivity between B and T cell subpopulations in the human nasopharynx (Figure 1C). We

127 also investigated whether Spn load was associated with cluster abundance to determine the effect

128 of cell clusters on the control of bacterial load. At day 2, four clusters were significantly negatively

129 correlated with Spn density, including the CD8^{dim} T cell cluster (r=-0.51, p=0.023) and one of the

130 CD161$^+$ CD8$^+$ T cell clusters (r=-0.51, p=0.021) that was increased in carriage$^-$ subjects over

131 carriage$^+$ subjects. The other two clusters that negatively associated with density were also were

132 CD8$^+$ T cell clusters, with one expressing CD161. At day 7, only two clusters were significantly

133 associated with Spn density: the CD8^{dim} T cell cluster (r=-0.55, p=0.011) and one B cell cluster (r=-

134 0.45, p=0.049).

Nasal B cells are depleted during pneumococcal carriage

136 We then further investigated the three B cell clusters that were higher in carriage$^-$ subjects (Figure

137 3A,B). All three significantly higher clusters (cluster 4, 9 and 17) expressed CD45RA, HLA-DR,

138 CD19, CCR6 and CCR7 to varying degrees. None of these clusters expressed CD38, a marker for

139 plasmablasts, or CD5, a marker for innate B cells (38, 39). Cluster 9 was 2.9-fold higher in carriage$^-$

140 subjects (p = 0.047) and cells in this cluster expressed also low levels of CXCR5 and CD27. Cluster

141 17 (2.0-fold higher, p = 0.049) additionally expressed the B cell activation marker CD69. To assess

142 whether the higher frequency in carriage$^-$ subjects was related to increased B cells in carriage$^-$

143 subjects or decreased B cells in carriage$^+$ subjects, we longitudinally measured CD19$^+$ B cell

144 frequencies in nasal microsamples collected from an independent cohort (Figure 3C and

145 Supplementary Figure 1A). Compared to baseline, B cell levels decreased following pneumococcal

146 carriage at days 2 (2.1-fold, p = 0.048), 6 (2.8-fold), 9 (2.0-fold) and 27 (3.1-fold, p = 0.028) post-

147 inoculation. In the carriage$^-$ group, B cell levels decreased 1.1-fold at days 2 and 6, increased 1.2-

148　fold at day 9 and decreased 1.2-fold at day 27, respectively and were thus relatively stable. The fold-

149　change decrease in nasal B cell levels did not associate with Spn density at any timepoint.

Pneumococcal carriage increases circulating plasmablasts

151　We hypothesized that the depletion of B cells from the nasal mucosa following carriage

152　establishment was due to a re-circulation of activated B cells. Although, none of the B cell clusters

153　that were lower in the carriage[+] group expressed the plasmablast marker CD38, it has been

154　demonstrated previously that memory B cells differentiate rapidly intro plasmablasts upon activation

155　(40). Therefore, we measured numbers of Spn-specific and total plasmablasts in peripheral blood

156　mononuclear cells (PBMC) collected before and after carriage establishment using a flow cytometry-

157　based assay (Supplementary Figure 1B). During carriage, the frequency of 6B polysaccharide-

158　specific plasmablasts among total B cells increased while the frequency of plasmablasts specific to

159　the pneumococcal protein pneumolysin remained unaltered (Figure 4A). As a negative control we

160　measured levels of plasmablasts specific for an unrelated Spn capsular type (15B), which were not

161　affected as expected. However, the frequency of total circulating plasmablasts among all B cells

162　increased (median 1.5x, IQR: 1.2-2.8x; p = 0.008) suggesting that nasal B cells became non-

163　specifically activated during carriage. Similar results were obtained when normalizing to the total

164　number of lymphocytes, demonstrating this was not due to other shifting B cell populations

165　(Supplementary Figure 2A). We then investigated CCR10 expression on these plasmablasts, which

166　has been reported to mark IgA secreting cells (41) and is potentially important for homing of B cells

167　to mucosal tissues including the airways (42, 43). The total population of plasmablasts post carriage

168　displayed reduced numbers of CCR10[+] cells, in contrast to 6B-specific plasmablasts, indicating

169　differential expansion between specific and non-specific B cell populations (Figure 4B). This is

170　supported by the observation that increased circulating levels of 6B polysaccharide-specific

171　plasmablasts inversely correlated with the nasal B cell CyTOF clusters 9 and 20, while total

172　plasmablast increases inversely correlated with the CyTOF B cell clusters 21 (Figure 4C). Clusters

173　9 and 21 still negatively correlated with levels of circulating 6B-specific and total plasmablasts,

174   respectively, after normalization to total lymphocyte numbers (Supplementary Figure 2B). Thus, we

175   wanted to assess whether both Spn-specific as well as unrelated B cells became activated following

176   carriage, leading to recirculation. We therefore measured antibody levels in serum against not only

177   Spn but also *Streptococcus pyogenes, Staphylococcus aureus* and *Haemophilus influenzae* as

178   these are common colonizers of the human nasopharynx and thus nasal B cells against these

179   bacterial species are likely present in the nose of most individuals. Following Spn colonization, IgG

180   levels specific for Spn (median 1.4x, IQR: 1.1-2.4) and *Haemophilus influenzae* (median 1.2x, IQR:

181   1.1-1.5) significantly increased, while IgG levels specific for *Streptococcus pyogenes* and

182   *Staphylococcus aureus* were not significantly altered (Supplementary Figure 3A). Serum IgA

183   concentration only increased for Spn and not for *Haemophilus influenzae* (Hi) or any of the other

184   bacterial species (Supplementary Figure 3B). To investigate whether this observed increase in

185   Haemophilus-specific IgG was due to an increase in cross-reactive antibodies, directed against for

186   example the surface antigen choline phosphate (ChoP) or the capsular polysaccharide (44, 45), we

187   also measured *Haemophilus*-specific IgG titers following absorption with whole cell pneumococcus

188   (Supplementary Figure 3C). This abrogated the increased titers against Hi post carriage, indicating

189   this was likely due to cross-reactivity. Similarly, in nasal wash, levels of IgA against Spn and Hi were

190   increased, whereby the latter also was prevented by pre-absorption of nasal wash with Spn

191   (Supplementary Figure 3D,E).

192   **Nasal CD8 Tissue-resident memory T cells are higher in carriage$^-$ subjects**

193   The three clusters of CD8$^+$ T cells and the cluster of CD8^{dim} T cells that were higher in carriage$^-$

194   subjects all expressed CD69, a marker of tissue-resident memory (Trm) cells (Figure 5A). To verify

195   that these CD69$^+$ CD8$^+$ T cells represented Trm cells, we measured the expression of CD103 and

196   CD49a on CD69$^+$ and CD69$^-$ cells by flow cytometry from a representative biopsy (Supplementary

197   Figure 4A). Indeed, 89.1% of nasal CD69$^+$ CD8$^+$ T cells expressed CD103 and CD49a, confirming

198   that these were Trm cells (Figure 5B) (46). The markers CD5, CD38, HLA-DR, CCR6, CD127, CCR7

199   and CD11c were expressed in cluster-specific patterns and at varying intensities among the

significant clusters. This suggests that clusters of cells with varying degrees of activation and memory types were enriched in carriage⁻ subjects. One cluster expressed only low levels of CD8 (cluster 10 of CD8^{dim} T cells, 2.0-fold higher, p = 0.016), which could reflect cytotoxic effector memory cells (47). We then stimulated nasal biopsy cells and PBMC overnight with PMA and ionomycin to assess the functional capacity of nasal CD8⁺ T cells (Figure 5C). Among nasal CD8⁺ T cells, 94.8% produced tumor necrosis factor alpha (TNF) and/or interferon gamma (IFN-ɣ) following stimulation, compared to 36% of blood CD8⁺ T cells, demonstrating that nasal CD8⁺ T cells are highly functional.

Baseline circulating MAIT functionality associates with resistance to pneumococcal carriage

Three of the four significant clusters expressed CD161, a marker for mucosal associated invariant T (MAIT) cells, and we therefore tested the hypothesis that MAIT cell responses against Spn were associated with protection against carriage. PBMC collected prior to pneumococcal challenge were stimulated *in vitro* with heat-inactivated Spn and activation (CD69) and cytokine production (TNF, IFN-ɣ and IL-17A) were assessed (Supplementary Figure 4B). MAIT cells of both carriage⁻ and carriage⁺ groups upregulated CD69 after a 3-day culture with heat-inactivated Spn (Supplementary Figure 4C). However, only MAIT cells from carriage⁻ subjects produced increased levels of TNF and IFN-ɣ, but not IL-17A, upon restimulation *in vitro* with heat-inactivated Spn (Figure 5D). Conversely, MAIT cells from carriage⁺ subjects did not produce increased levels of any cytokine upon stimulation. This was specific to MAIT cells as conventional CD8⁺ T cells responded by producing small amounts of IFN-ɣ and no TNF (Supplementary Figure 4D). The baseline responses of MAIT cells in blood upon restimulation showed a positive correlation with numbers of nasal cells at ten days post pneumococcal challenge in CyTOF CD161⁺ CD8⁺ T cell cluster 9, which was significantly higher in the carriage⁻ group (r = 0.54, p = 0.02, Figure 5E).

To assess the kinetics of nasal MAIT cells, we collected nasal curettes before and at 2 and 6 days post inoculation in an independent cohort and analysed total MAIT cells by flow cytometry (Supplementary Figure 5). Total MAIT cell numbers were similar between carriage⁻ and carriage⁺ groups at all timepoints, as observed by CyTOF at day 10. Due to the low numbers of cells that can

226 be obtained using minimally-invasive curettage, we were not able to longitudinally measure MAIT

227 cell subsets that were significantly associated with carriage as identified by CyTOF.

228 **Association between baseline IgG and abundance of B and CD8[+] T cell clusters**

229 We wanted to further characterize the relationship between abundance of the clusters that were

230 significantly different between carriage[+] and carriage[−] groups with levels of baseline IgG against Spn

231 to assess whether recall responses were involved. As previously reported, there was no difference

232 between carriage[+] and carriage[−] groups in levels of baseline IgG against Spn (Figure 6A) (7, 25, 27).

233 Of the seven clusters significantly associated with carriage status, one cluster (B cell cluster 9)

234 showed a positive association between baseline IgG and cluster abundance (Figure 6B). This B cell

235 cluster also correlated with the increased number of 6B-specific plasmablasts following colonization,

236 which could suggest that these B cells are linked to production of Spn 6B-specific antibodies.

237 **Nasal monocytes show limited differentiation into macrophages**

238 Monocytes have been previously associated with the clearance of Spn carriage (16, 23), however

239 these cells have not been previously phenotyped in detail in the human nasopharynx. Of the twenty-

240 five clusters defined in the myeloid lineage, fifteen expressed CD14 (Supplementary Figure 6). Of

241 these, only two also expressed CD16. Four CD14[+] clusters expressed the macrophage markers

242 CD163 and CD206 and an additional three clusters expressed CD206 but not CD163 (48). However,

243 alveolar monocytes can express CD206, suggesting this is not a definitive indication of differentiation

244 (49). The activation markers CD25 and CD86 were present on five monocyte clusters (50). Thus,

245 monocyte/macrophages in the nose mainly consisted of classical monocytes with limited

246 differentiation into macrophages.

247 **Characterization of nasal CD4[+] memory T cells**

248 CD4[+] T memory cells, in particular Th17 cells, were previously found to be critical for Spn immunity

249 in mice models of nasal colonization (15, 16). Of all cells in the CD4[+] T cell lineage, 89.6% expressed

250   the memory marker CD45RO. Of these, 60.3% expressed CD161, a marker that has been proposed

251   to identify Th17 cells (51, 52). Another 4.6% of memory cells was defined by expression of high

252   levels of CD25, a marker for regulatory T cells. We defined twenty-three clusters of CD161$^-$ CD4$^+$ T

253   memory cells, twenty-one clusters of CD161$^+$ CD4$^+$ T memory cells and nine clusters of CD25^{hi} CD4$^+$

254   T memory cells (Supplementary Figure 7). All CD4$^+$ T memory cell clusters expressed a combination

255   of the markers CD7, CD127, HLA-DR, CD38 and CD69 demonstrating a wide range in activation

256   and differentiation status (46). The CD25^{hi} CD4$^+$ T memory cells likely were regulatory T cells as

257   they were predominantly negative for CD127 and two of these clusters expressed cytotoxic T-

258   lymphocyte-associated protein 4 (CTLA-4) and CD27 (53). CD161 was not restricted to Th17 cells

259   as among CD161$^+$ CD4$^+$ T memory cells, two clusters expressed also CD8 and were thus double-

260   positive T cells (54). In addition, two clusters expressed CD25 without CD127 expression indicating

261   regulatory T cells, and one cluster expressed chemoattractant receptor-homologous molecule

262   expressed on Th2 cells (CRTH2), a marker of Th2 cells (55).

263   **Cellular distribution through the nasal mucosa**

264   We then performed immunohistochemistry on a biopsy from a challenged but carriage$^-$ subject to

265   further understand the distribution of these cells through the mucosal tissue (Figure 7). CD4$^+$ T cells

266   were found predominantly in the subepithelial layer (Figure 7C,D), while CD8 and CD161 were also

267   found at the epithelial layer (Figure 7E,F). Similar to CD4$^+$ T cells, B cells (defined by CD20) were

268   mostly observed in the sub-epithelium, while myeloid cells (CD68) could be seen at both the

269   epithelial and sub-epithelial layer (Figure 7G,H). Neutrophils were found abundantly at the epithelial

270   surface but also in the sub-epithelium (Figure 7I,J).

271   **Discussion**

272   This study comprehensively characterised immune cells in biopsies collected from the human nasal

273   mucosa. As nasal samples were collected ten days following experimental human pneumococcal

274   challenge, we were able to associate the frequency of specific immune populations with Spn

11

275 carriage. Given the difficulty in access to such tissue samples, especially in a setting where the onset

276 of infection is known, this provided a unique opportunity to investigate mucosal immune responses

277 not undertaken previously. The application of CyTOF led to a broad and comprehensive study of

278 cellular subsets involved in immunity against Spn carriage, deriving 293 immune clusters belonging

279 to nine cellular lineages. Clusters belonging to B cells and CD8$^+$ CD161$^+$ T cells were higher in

280 carriage$^-$ subjects. In addition to carriage status, we also associated Spn density with cluster

281 abundance. Several CD8$^+$ T cell clusters negatively correlated with Spn load, further supporting a

282 protective function for these cells.

283 B cells were depleted from the nasal mucosa following the establishment of Spn carriage. This

284 depletion correlated on an individual level with increased numbers of circulating 6B polysaccharide

285 specific and total plasmablasts. Thus, this depletion likely was due to recirculation of activated B

286 cells rather than due to apoptosis of nasal B cell upon Spn polysaccharide capsule encounter as has

287 also been described (56). The total plasmablast expansion, but not 6B plasmablast expansion, was

288 characterized by a decreased proportion of CCR10$^+$ cells, suggesting a preferential expansion of

289 CCR10$^-$ cells or a downregulation of this marker. The correlation between low numbers of cells in

290 specific nasal B cell clusters with increased levels of circulating plasmablasts indicates that activation

291 of nasal B cells during carriage led to B cell re-circulation. In particular numbers of B cell cluster 9,

292 which was lower in carriage$^+$ subjects, associated with 6B PS-specific plasmablasts, as well as with

293 levels of pneumococcus-specific antibodies in serum. Indeed, trafficking of memory B cells between

294 airways and blood has been reported (57).

295 Levels of serum IgG against Hi increased following colonization with Spn, due to an induction of

296 cross-reactive antibodies, as pre-absorption with Spn abrogated this increase. Thus, pneumococcal

297 colonization has an effect on mucosal and systemic B cell populations and antibodies that bind both

298 pneumococcus and Hi. The negative association between Spn and Hi in the human nasopharynx is

299 well described and this observation could be added to the potential mechanisms that underlie this

300 interaction, such as Hi-mediated recruitment of neutrophils and clearance of pneumococcus (58). B

301　cells express the innate receptors TLR2 and TLR4 (59), which can be activated by pneumococcus,

302　and we thus hypothesized that pneumococcal carriage leads to non-specific activation of B cells.

303　*Neisseria lactamica* has been previously demonstrated to be able to aspecifically activate innate B

304　cells (60, 61). However, the increased antibody responses against Hi were likely due to induction of

305　cross-reactive antibodies and we observed no increase in serum IgG levels against *Streptococcus*

306　*pyogenes* or *Staphylococcus aureus*, two other common nasal colonizers.

307　Several nasal CD8$^+$ Trm cell clusters were higher in subjects protected from Spn carriage. These

308　cells were previously found to be protective against influenza infection in murine models (62). Spn

309　is classically thought of as an extracellular bacterium and therefore the role of CD8$^+$ T cells in

310　controlling Spn has not been extensively studied in humans. However, it was recently shown that

311　Spn can replicate within splenic macrophages and can reside within epithelial cells, suggesting that

312　CD8$^+$ T cell immunity could be elicited by Spn and play a role in protection against Spn carriage or

313　disease (63, 64). Indeed, Spn protein specific CD8$^+$ T cells could be readily detected in blood of

314　Gambian adults (65). In murine models, CD8$^+$ T cells were found to be protective against Spn lung

315　infection but did not have an effect on nasopharyngeal carriage (19, 66).

316　We found here that CD8$^+$ MAIT cell functionality before pneumococcal challenge associated with a

317　resistance to carriage acquisition. MAIT cells were recently reported to be able to recognize Spn

318　through MHC class I-related protein 1 (MR-1) dependent and independent pathways (67). MAIT cells

319　were previously found to be important in the protection against lung bacterial and viral infections via

320　direct and indirect responses (68). Our findings now suggest these cells could also protect against

321　nasopharyngeal Spn colonization. Given the abundance of MAIT cells at the nasal mucosa and their

322　specificity for precursors from the riboflavin synthesis pathway, which is highly conserved in the Spn

323　genome (67), these cells are excellently placed to initiate an immune response upon exposure to

324　Spn. The rapid production of cytokines as TNF and IFN-γ by these cells upon Spn encounter could

325　lead to the recruitment or activation of neutrophils and monocytes, which in turn could phagocytose

326　Spn and protect against carriage acquisition (69). Baseline MAIT functionality in blood positively

13

correlated with cell numbers within one of the nasal CD8$^+$ CD161$^+$ cell clusters, suggesting trafficking of MAIT cells from the blood to the nose upon pneumococcal encounter. Indeed, MAIT cells have been shown to be depleted from the circulation and accumulate in tissues upon infection (70, 71).

One limitation of this study is that the number of granulocytes measured was very low due to the overnight resting step following enzymatic digestion. While this resting step allowed for the return of markers that were cleaved by the enzymatic digestion, neutrophils quickly become apoptotic after being removed from the body (72-74). Consequently, the characterization of granulocytes reported here is incomplete and we were not able to assess whether specific neutrophil subsets are associated with protection against pneumococcal colonization.

In addition, due to the invasiveness of sample acquisition, sample size was limited and we were not able to characterize nasal biopsies at various time points. Thus, no baseline was available making it impossible to conclude whether differences between carriage$^-$ and carriage$^+$ groups were present at baseline or occurred in the ten days following inoculation. In addition, we were not able to assess transient responses early after bacterial inoculation. To address this caveat, we longitudinally measured levels of nasal B cells and MAIT cells collected by nasal curettes in independent cohorts. This analysis demonstrated that B cells were depleted from the nose upon colonization. In contrast, we did not observe any changes in total numbers of MAIT cells. Using CyTOF we observed that MAIT cell clusters expressing the markers CD7, CD69, CD5 and CCR6 or CD38, but not total number of MAIT cells, were higher in the carriage$^-$ group. Thus the larger amount of cells obtained from nasal biopsies combined with the broad analysis by CyTOF allowed us to identify sub-populations of MAIT cells associated with protection against colonization.

This study revealed some notable differences from previously conducted experiments with murine models. In particular, we did not see any association between Th17 cells, or any CD4+ T memory cells, and control of colonization as previously reported (15, 16). This agrees with previous observations from experimentally colonized adults that nasal IL-17A levels are not increased (24). Moreover, there was no association between monocytes and Spn colonization status or density,

14

unlike what was previously reported in murine models or humans followed up longitudinally following experimental colonization (16, 20, 24). This is possibly because we terminated carriage after day seven for safety reasons prior to collecting biopsies, making it impossible to associate immune cell clusters, such as monocytes, with Spn clearance which typically occurs after day 10. Moreover due to relatively small numbers of individuals in this controlled human infection study, it is possible that subtle associations between cell populations and bacterial load were missed. This study however does provide a unique characterization of monocytes/macrophages phenotype in the human nose, which show remarkably little differentiation into macrophages. Another remarkable difference between this study and findings from murine models is that we observed a protective effect of MAIT cells against colonization, while depletion of CD8[+] T did not affect immunological Spn control in mouse models (19). MAIT cells are a recently identified T cell subset that is common in humans, consisting of up to 10% of all T cells in the circulation, but that is very rare in mice (68). It is possible that this difference has led to an underappreciation of the CD8[+] T cell's role in protection against pneumococcal carriage in humans. Finally, our finding of an activation and exodus of B cells from the nose merits further attention and validation using tractable mouse models to understand its role in the generation of humoral immunity against Spn and cross-reactive protection against *Haemophilus influenzae*.

In conclusion, this study provides both a broad and an in-depth view of the adult human nasal immune system in the setting of experimental human pneumococcal challenge. Nasal B cells were depleted following carriage establishment, likely due to differentiation to plasmablasts and recirculation. In addition, CD8[+] MAIT cell responses were associated with protection from Spn carriage.

Methods

Study design and sample collection

Healthy adult subjects were screened for the presence of natural pneumococcal carriage in nasal wash samples (NW) using classical microbiology (7, 34, 75). Subjects not naturally carrying

15

379   pneumococcus were then inoculated with 80,000 CFU per nostril of 6B type Spn as described (7,

380   75). Development of nasal carriage was monitored using NW samples collected at days 2 and 7 post

381   inoculation. Growth of pneumococcus from NW samples at any time-point defined carriage positive

382   volunteers. All subjects then received a three-day course of amoxicillin and underwent a 4mm nasal

383   biopsy at day 10 post inoculation. The nasal cavity was first sprayed up to six times with lidocaine

384   hydrochloride 5% with phenylephrine hydrochloride 0.5%. Five to ten minutes later the infero-medial

385   part of the inferior turbinate, i.e. the point of incision, was injected with up to 1 mL of lidocaine

386   hydrochloride 2% with adrenaline 1:80 000. An incision of approximately 5 mm with No.15 blade was

387   then made and 2-4 mm of mucosal tissue was removed with Tillies Henckle's surgical forceps. This

388   study was registered under ISRCTN85509051. Nasal curettes (ASL Rhino-Pro©, Arlington

389   Scientific) were collected from an additional cohort (ISRCTN16993271) of subjects inoculated with

390   the same 6B strain. The outcomes reported in this manuscript were a priori included in the study

391   protocols.

392   **Nasal biopsy digestion**

393   Nasal biopsies were finely cut using a sterile scalpel size 11 (Fisher Scientific). Pieces were then

394   incubated in 20mL pre-warmed RPMI 1640 (Fisher Scientific) with Liberase TL (250µg/mL, Sigma)

395   and DNAse I (50µg/mL, Sigma). Fragments were incubated for 45 minutes at 37°C, while shaking

396   at 250rpm at a 10° angle. At the end of the digestion, biopsies were passed five times through a 16-

397   gauge blunt-ended needle (Fisher Scientific) and the digested sample was filtered over a 70um filter

398   (Fisher Scientific). This process was repeated for any remaining fragments. Cell were spun down for

399   10 minutes at 400xg and then red blood cells were lysed using an osmotic lysis buffer. Cells were

400   washed with RPMI with 20% heat-inactivated fetal bovine serum (FBS, Fisher Scientific),

401   resuspended at 10^6 cells/mL in RPMI with 20% FBS and rested overnight. The next day, cells were

402   counted and washed with RPMI + 10% FBS. Cells were stained as a viability marker using 1µM

403   intercalator Rh-103 (Fluidigm) for 15 minutes, washed and fixed with 1.8% paraformaldehyde

404 (Sigma) for 15 minutes. Cells were washed and stored in liquid nitrogen in CTL-Cryo^{TM} ABC media

405 (Cellular Technology Limited) until CyTOF barcoding and staining.

Mass cytometry staining and analysis

407 Nasal biopsy cells were thawed on ice and barcoded using the Cell-ID 20-plex Pd Barcoding Kit as

408 per manufacturer's instructions (Fluidigm). The effect of fixation on epitopes detected by the included

409 antibody clones was tested using PBMCs and monocyte-derived dendritic cells. Following three

410 washes with staining buffer (Fluidigm) and 10 minutes of FcR blocking (Biolegend) pooled cells were

411 stained for 45 minutes at room temperature with the antibody cocktail (Supplementary Table 1). All

412 Fluidigm antibodies were pre-conjugated to metals while all other antibodies were conjugated using

413 a total of 100 µg of purified antibody combined with the MaxPar X8 Antibody Labelling Kit (Fluidigm)

414 according to manufacturer's protocol V7 and stored in 200 µL Antibody Stabilizer PBS (Candor

415 Bioscience) at 4°C. Cells were washed twice with staining buffer and incubated for 1 hour with 1000x

416 diluted 125 µM Cell-ID intercalator-Ir (Fluidigm) to stain DNA. Cells were washed 3 times with

417 staining buffer and 2 times with de-ionized H$_2$O prior to addition of normalization beads (Fluidigm)

418 and acquisition on a Helios 2 mass cytometer (DVS Sciences). CyTOF Fcs files were normalized

419 using the included beads, concatenated and debarcoded as per manufacturer's instructions. The

420 debarcoding step leads to a removal of doublets (76). Then, viable immune cells were pre-grated

421 (Figure 2) and exported as .fcs files using Flowjo X (Treestar). These were further analysed using

422 Cytosplore (https://www.cytosplore.org/).

Nasal B and MAIT cell phenotyping

424 Immunophenotyping of nasal B and MAIT cells obtained by curettes was performed as described

425 (29). In brief, cells were dislodged from curettes and stained with LIVE/DEAD® Fixable Aqua Dead

426 Cell Stain (ThermoFisher) and an antibody cocktail containing among others Epcam-PE, HLADR-

427 PECy7, CD66b-FITC, CD19-BV650 (all Biolegend), CD3-APCCy7, CD14-PercpCy5.5 (BD

428 Biosciences) and CD45-PACOrange (ThermoFisher) for B cells, while the cocktail for MAIT cells

429 included also CD8–BV785 and TCRva7.2-BV711 or TCRva7.2-PE-TxsRed and CD45-BV510

17

430 (Biolegend). Samples were acquired on a LSRII flow cytometer and analysed using Flowjo X

431 (Treestar). Fluorescent minus one controls for each of the included antibodies were used to validate

432 results during set-up of all of the panels used. Samples with less than 500 immune cells or 250

433 epithelial cells (11.9% of all nasal samples) were excluded from further analysis. A full list of all

434 antibodies used for flow cytometry is provided in Supplementary Table 2).

435 **Intracellular cytokine staining following PMA/Ionomycin or pneumococcus stimulation**

436 For intracellular cytokine staining after PMA and Ionomycin stimulation, fresh nasal biopsy cells or

437 PBMC were stimulated with 100 and 500 ng/mL of these, respectively. After 2 hours, Golgiplug™

438 (BD Biosciences) was added and cells were incubated for another 16 hours. Cells were washed and

439 stained extracellularly with LIVE/DEAD® Fixable Violet Dead Cell Stain (ThermoFisher) for 15

440 minutes and then for another 15 minutes with CD161-APC, CD69-BV650, CD25-PEDazzle594,

441 CD103-BV605, CD4-PercpCy5.5, CD8-AF700, TCRvα7.2-BV785 (all Biolegend) and CD3-APH7

442 and TCRgd-PECy7 (BD Biosciences). Cells were then permeabilized using the eBioscience™ Foxp3

443 Transcription Factor Staining Buffer Set (Fisher Scienctific) following the manufacturer's protocol.

444 Intracellular staining was done for 30 minutes with FOXP3-AF488, IFNg-PE, TNFa-BV711

445 (Biolegend) and IL17A-BV510 (BD Biosciences). Finally, cells were washed, resuspended in 200μL

446 PBS and acquired on a LSR2.

447 For staining with pneumococcus, PBMC were thawed with 50μg/mL DNAse I (Sigma) in pre-warmed

448 RPMI + 10% FBS and washed twice, once in media including DNAse I and once in media without

449 DNAse I. Cells were rested overnight and then cultured at 5×10^5 cells in 500uL media with 5ug/mL

450 (corresponding to 4.3x10^7 CFU/mL) heat-inactivated type 6B *Streptococcus pneumoniae* or left

451 unstimulated as a control. After 48 hours, fresh antigen was added to the cells and 2 hours later

452 Golgiplug was added and cells were treated as above.

453 **Pneumococcal-specific B cell detection**

454   Purified pneumococcal polysaccharides 6B and 15B (Oxford Biosystems) and Pdb were diluted to

455   100µg/mL in purified H_2O and biotinylated using the One-Step Antibody Biotinylation Kit (Miltenyi)

456   as per manufacturer's instructions. Biotinylated proteins were then 2x dialysed for 45 minutes against

457   1L PBS using Slide-A-Lyzer™ MINI Dialysis Device, 3500 molecular weight cut off (ThermoFisher)

458   and stored at 4ºC until labelling. Biotinylated 15B, 6B and Pdb were then mixed in a 4:1 molecular

459   ratio (Pdb), or a 1:1 molecular ratio (polysaccharides), with PE-streptavidin, BV785-streptavidin or

460   FITC-streptavidin (Biolegend), respectively. Incubation was performed on ice in a stepwise approach

461   where 1/10 fraction of streptavidin conjugate was added to the antigen followed by a ten-minute

462   incubation. After the final incubation, 1 pmol free biotin was added and the mixture was incubated

463   for 30 minutes on ice. Labelled antigens were stored at 4ºC and used within two weeks.

464   To stain cells, PBMC were thawed with 50µg/mL DNAse I (Sigma) in pre-warmed RPMI + 10% FBS

465   and washed once in media including DNAse I. Cells were then resuspended in PBS containing

466   LIVE/DEAD® Fixable Violet Dead Cell Stain (ThermoFisher) with 10µg/mL purified streptavidin (to

467   block aspecific binding, Biolegend) for 15 minutes. Then labelled antigens and an antibody cocktail

468   containing CD71-AF700 (BD Biosciences), CD19-BV605, CD27-PE/Cy7, CD38-APC/Cy7, CD69-

469   BV510 and CCR10-APC (all Biolegend) was added and cells were incubated for another 15 minutes.

470   Finally, cells were washed, resuspended in 200µL PBS and acquired on a LSR2.

471   **Immunohistochemistry**

472   A nasal biopsy was fixed in 4% PFA for 16-24 hours before rinsing in 50% and 70% ethanol. This

473   was embedded in Paraffin, cut into 4µm sections, dewaxed, subjected to antigen retrieval (95ºC for

474   15 minutes in Sodium Citrate Buffer (pH 6) and processed for immunohistochemistry as published

475   (77). In short, sections were permeabilised in methanol for 15 minutes with 1% hydrogen peroxide.

476   After rinsing in PBS, primary antibodies were diluted in goat (or horse) serum buffer (1% BSA, 4%

477   goat (or horse) serum, 0.01% sodium azide in PBS). Primary antibodies used were: CD3 (Dako),

478   CD4, CD20, CD66b, CD68, CD11b (Abcam), CD8 (Epitomics) and CD161 (Atlas antibodies), which

479   were applied over night at 4ºC (Supplementary table 3). Sections were rinsed in PBS and secondary

19

480 biotinylated antibodies (Vector lab) were applied for 45 mins at RT. Slides were rinsed and a complex

481 of avidin and biotin (ABC) solution was added to sections for 60 minutes which was prepared 30

482 minutes prior incubation After rinsing, NovaRed™ (Vector®, Burlingame, CA, U.S.A) chromogen

483 was prepared to manufacturer's instructions. Sections were counterstained, dehydrated, placed in

484 xylene and mounted for microscopy and scanned using the nanozoomer digital pathology (NDP,

485 Hamamatsu, Photonics KK). Pictures were processed using the NDPview 2 software (version 2.6.13;

486 Hamamatsu Photonics KK).

487 **ELISA**

488 Serum IgG and IgA titres against *Streptococcus pneumoniae, Streptococcus pyogenes,*

489 *Staphylococcus aureus* and *Haemophilus influenzae* were quantified in serum samples, whereas

490 nasal mucosa IgG and IgA titres against Streptococcus pneumoniae and Haemophilus influenzae

491 were measured in nasal wash samples using whole cell ELISA. The ELISA was performed on

492 MaxiSorp™ 96 well plates (Nunc). Per pathogen, 100µL of 10^8 CFU/mL was prepared in carbonate

493 buffer pH 8, added to the plates and allowed to adhere to the wells for 16 hours at 22°C. Then the

494 plates were washed three times using phosphate buffered saline (PBS) containing 0.05% Tween 20,

495 followed by blocking by adding 100 µL of PBS containing 2% Bovine serum albumin. Plates were

496 incubated at 37°C for 1 hour and were washed before adding serial dilutions of serum samples. For

497 detection of IgG and IgA, a 1:5000 and 1:4000 dilution of anti-human-IgG (Sigma, A9544, Germany)

498 and anti-human-IgA (Sigma, A9669, Germany), respectively, was made using 0.1% BSA and 100

499 µL added to each well after washing and incubated at room temperature for 2 hours. Standard curves

500 for IgG and IgA were generated based on a standard pool serum (sera of 7 Spn carriers collected at

501 D23 post challenge). Arbitrary units of IgG and IgA were assigned to the serum standard for each

502 pathogen. To absorb antibodies cross-reactive against S. pneumoniae, pneumococci were added in

503 the samples, following 2h incubation at RT and overnight incubation on a rotor at 4o C. The next day

504 samples were centrifuged at 4,000g for 3min and supernatant was collected and measured as

505 above. Efficacy of depletion was confirmed by ELISA against Spn post absorption.

Statistics

Two-tailed, non-parametric statistical tests were used throughout the study. The number of cells in

a cluster for each subject was normalized against the total number of non-immune cells acquired by

CyTOF for that subject to account for number of cells isolated from a given biopsy. This normalization

strategy has the advantage that the normalized frequencies of cells in a cluster is not dependent on

other clusters, which is a major disadvantage of normalizing against total immune cells. Normalized

cluster abundances were then compared between carriage$^-$ and carriage$^+$ subjects for each of the

clusters using the Mann-Whitney test, without correcting for multiple testing. Data was analysed and

graphs were created using 'pheatmap' and 'ggplot2' packages in R software and circular graph

(Figure 1C) was created using circos software (78). The graphical abstract was created with

BioRender

Data availability

Normalized and debarcoded CyTOF fcs files have been deposited in the FlowRepository with

identifier FR-FCM-ZYSE (https://flowrepository.org/).

Study Approval

All subjects gave written informed consent and research was conducted in compliance with all

relevant ethical regulations. Ethical approval was given by the East Liverpool NHS Research and

Ethics Committee (REC), reference numbers: 17/NW/0029 and 14/NW/1460.

Author contributions

SJ contributed to conceiving, designing, conducting and analysing experiments, design of the study and writing of the paper. KR, CS, AV contributed to designing, conducting and analysing experiments. SG, LL, JRylance, AC, SL contributed to conceiving and designing the study. EM, EN, BC, AS, SP, EG, JReine, CW and PD contributed to conducting and analysing experiments. HH, RR, AHW, SL and MW contributed to sample collection. RSH, HS, BU and MY contributed to designing and analysing experiments. DF contributed to conceiving, designing and analysing experiments, design of the study and writing of the paper. All authors have read and approved the manuscript. The authorship order between shared fist and shared senior authors was decided alphabetically.

References

549 1. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, et al. Burden of
550   disease caused by Streptococcus pneumoniae in children younger than 5 years: global
551   estimates. *Lancet.* 2009;374(9693):893-902.
552 2. Welte T, Torres A, and Nathwani D. Clinical and economic burden of community-acquired
553   pneumonia among adults in Europe. *Thorax.* 2012;67(1):71-9.
554 3. Ortqvist A, Hedlund J, and Kalin M. Streptococcus pneumoniae: epidemiology, risk factors,
555   and clinical features. *Semin Respir Crit Care Med.* 2005;26(6):563-74.
556 4. Goldblatt D, Hussain M, Andrews N, Ashton L, Virta C, Melegaro A, et al. Antibody
557   Responses to Nasopharyngeal Carriage of Streptococcus pneumoniae in Adults: A
558   Longitudinal Household Study. *Journal of Infectious Diseases.* 2005;192(3):387-93.
559 5. Simell B, Auranen K, Kayhty H, Goldblatt D, Dagan R, O'Brien KL, et al. The fundamental
560   link between pneumococcal carriage and disease. *Expert review of vaccines.*
561   2012;11(7):841-55.
562 6. Melegaro A, Gay NJ, and Medley GF. Estimating the transmission parameters of
563   pneumococcal carriage in households. *Epidemiol Infect.* 2004;132(3):433-41.
564 7. Ferreira DM, Neill DR, Bangert M, Gritzfeld JF, Green N, Wright AK, et al. Controlled
565   human infection and rechallenge with Streptococcus pneumoniae reveals the protective
566   efficacy of carriage in healthy adults. *American journal of respiratory and critical care
567   medicine.* 2013;187(8):855-64.
568 8. McCool TL, Cate TR, Moy G, and Weiser JN. The immune response to pneumococcal
569   proteins during experimental human carriage. *JExpMed.* 2002;195(3):359.
570 9. Weiser JN, Ferreira DM, and Paton JC. Streptococcus pneumoniae: transmission,
571   colonization and invasion. *Nat Rev Microbiol.* 2018;16(6):355-67.
572 10. Granat SM, Ollgren J, Herva E, Mia Z, Auranen K, and Makela PH. Epidemiological
573   evidence for serotype-independent acquired immunity to pneumococcal carriage. *The
574   Journal of infectious diseases.* 2009;200(1):99-106.
575 11. Weinberger DM, Dagan R, Givon-Lavi N, Regev-Yochay G, Malley R, and Lipsitch M.
576   Epidemiologic evidence for serotype-specific acquired immunity to pneumococcal carriage.
577   *The Journal of infectious diseases.* 2008;197(11):1511-8.
578 12. Cobey S, and Lipsitch M. Niche and neutral effects of acquired immunity permit
579   coexistence of pneumococcal serotypes. *Science.* 2012;335(6074):1376-80.
580 13. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al. Decline in
581   invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate
582   vaccine. *N Engl J Med.* 2003;348(18):1737-46.
583 14. Jochems SP, Weiser JN, Malley R, and Ferreira DM. The immunological mechanisms that
584   control pneumococcal carriage. *PLoS Pathog.* 2017;13(12):e1006665.
585 15. Lu YJ, Gross J, Bogaert D, Finn A, Bagrade L, Zhang Q, et al. Interleukin-17A mediates
586   acquired immunity to pneumococcal colonization. *PLoS Pathog.* 2008;4(9):e1000159.
587 16. Zhang Z, Clarke TB, and Weiser JN. Cellular effectors mediating Th17-dependent clearance
588   of pneumococcal colonization in mice. *J Clin Invest.* 2009;119(7):1899-909.
589 17. Lu YJ, Leite L, Goncalves VM, Dias Wde O, Liberman C, Fratelli F, et al. GMP-grade
590   pneumococcal whole-cell vaccine injected subcutaneously protects mice from
591   nasopharyngeal colonization and fatal aspiration-sepsis. *Vaccine.* 2010;28(47):7468-75.
592 18. McCool TL, and Weiser JN. Limited role of antibody in clearance of Streptococcus
593   pneumoniae in a murine model of colonization. *Infect Immun.* 2004;72(10):5807-13.

594   19.   Malley R, Trzcinski K, Srivastava A, Thompson CM, Anderson PW, and Lipsitch M. CD4+
595   T cells mediate antibody-independent acquired immunity to pneumococcal colonization.
596   *Proc Natl Acad Sci U S A.* 2005;102(13):4848-53.

597   20.   Davis KM, Nakamura S, and Weiser JN. Nod2 sensing of lysozyme-digested peptidoglycan
598   promotes macrophage recruitment and clearance of S. pneumoniae colonization in mice. *J*
599   *Clin Invest.* 2011;121(9):3666-76.

600   21.   Kuipers K, Lokken KL, Zangari T, Boyer MA, Shin S, and Weiser JN. Age-related
601   differences in IL-1 signaling and capsule serotype affect persistence of Streptococcus
602   pneumoniae colonization. *PLoS Pathog.* 2018;14(10):e1007396.

603   22.   Parker D, Martin FJ, Soong G, Harfenist BS, Aguilar JL, Ratner AJ, et al. Streptococcus
604   pneumoniae DNA initiates type I interferon signaling in the respiratory tract. *MBio.*
605   2011;2(3):e00016-11.

606   23.   Jochems SP, Marcon F, Carniel BF, Holloway M, Mitsi E, Smith E, et al. Inflammation
607   induced by influenza virus impairs human innate immune control of pneumococcus. *Nat*
608   *Immunol.* 2018.

609   24.   Jochems SP, Marcon F, Carniel BF, Holloway M, Mitsi E, Smith E, et al. Inflammation
610   induced by influenza virus impairs human innate immune control of pneumococcus. *Nat*
611   *Immunol.* 2018;19(12):1299-308.

612   25.   Pennington SH, Pojar S, Mitsi E, Gritzfeld JF, Nikolaou E, Solorzano C, et al.
613   Polysaccharide-specific Memory B-cells Predict Protection Against Experimental Human
614   Pneumococcal Carriage. *American journal of respiratory and critical care medicine.* 2016.

615   26.   Collins AM, Wright AD, Mitsi E, Gritzfeld JF, Hancock CA, Pennington SH, et al. First
616   Human Challenge Testing of a Pneumococcal Vaccine. Double-Blind Randomized
617   Controlled Trial. *American journal of respiratory and critical care medicine.*
618   2015;192(7):853-8.

619   27.   Mitsi E, Roche AM, Reine J, Zangari T, Owugha JT, Pennington SH, et al. Agglutination by
620   anti-capsular polysaccharide antibody is associated with protection against experimental
621   human pneumococcal carriage. *Mucosal Immunol.* 2016.

622   28.   Khan MN, and Pichichero ME. The host immune dynamics of pneumococcal colonization:
623   implications for novel vaccine development. *Hum Vaccin Immunother.* 2014;10(12):3688-
624   99.

625   29.   Jochems SP, Piddock K, Rylance J, Adler H, Carniel BF, Collins A, et al. Novel Analysis of
626   Immune Cells from Nasal Microbiopsy Demonstrates Reliable, Reproducible Data for
627   Immune Populations, and Superior Cytokine Detection Compared to Nasal Wash. *PLoS*
628   *One.* 2017;12(1):e0169805.

629   30.   Spitzer MH, and Nolan GP. Mass Cytometry: Single Cells, Many Features. *Cell.*
630   2016;165(4):780-91.

631   31.   Li N, van Unen V, Hollt T, Thompson A, van Bergen J, Pezzotti N, et al. Mass cytometry
632   reveals innate lymphoid cell differentiation pathways in the human fetal intestine. *J Exp*
633   *Med.* 2018;215(5):1383-96.

634   32.   Morrell ED, Wiedeman A, Long SA, Gharib SA, West TE, Skerrett SJ, et al. Cytometry
635   TOF identifies alveolar macrophage subtypes in acute respiratory distress syndrome. *JCI*
636   *Insight.* 2018;3(10).

637   33.   Rylance J, de Steenhuijsen Piters WA, Pojar S, Nikolaou E, German E, Mitsi E, et al. Effect
638   of Live Attenuated Influenza Vaccine on Pneumococcal Carriage. *bioRxiv.* 2018.

639   34.   Gritzfeld JF, Cremers AJ, Ferwerda G, Ferreira DM, Kadioglu A, Hermans PW, et al.
640   Density and duration of experimental human pneumococcal carriage. *Clin Microbiol Infect.*
641   2014;20(12):O1145-51.

642 35. Hollt T, Pezzotti N, van Unen V, Koning F, Eisemann E, Lelieveldt B, et al. Cytosplore:
643 Interactive Immune Cell Phenotyping for Large Single-Cell Datasets. *Comput Graph*
644 *Forum.* 2016;35(3):171-80.
645 36. van Unen V, Hollt T, Pezzotti N, Li N, Reinders MJT, Eisemann E, et al. Visual analysis of
646 mass cytometry data by hierarchical stochastic neighbour embedding reveals rare cell types.
647 *Nat Commun.* 2017;8.
648 37. Abdelmoula WM, Pezzotti N, Holt T, Dijkstra J, Vilanova A, McDonnell LA, et al.
649 Interactive Visual Exploration of 3D Mass Spectrometry Imaging Data Using Hierarchical
650 Stochastic Neighbor Embedding Reveals Spatiomolecular Structures at Full Data
651 Resolution. *J Proteome Res.* 2018;17(3):1054-64.
652 38. Jourdan M, Caraux A, Caron G, Robert N, Fiol G, Reme T, et al. Characterization of a
653 transitional preplasmablast population in the process of human B cell to plasma cell
654 differentiation. *J Immunol.* 2011;187(8):3931-41.
655 39. Hardy RR. B-1 B cell development. *J Immunol.* 2006;177(5):2749-54.
656 40. Tangye SG, Avery DT, Deenick EK, and Hodgkin PD. Intrinsic differences in the
657 proliferation of naive and memory human B cells as a mechanism for enhanced secondary
658 immune responses. *J Immunol.* 2003;170(2):686-94.
659 41. Morteau O, Gerard C, Lu B, Ghiran S, Rits M, Fujiwara Y, et al. An indispensable role for
660 the chemokine receptor CCR10 in IgA antibody-secreting cell accumulation. *J Immunol.*
661 2008;181(9):6309-15.
662 42. Kato A, Hulse KE, Tan BK, and Schleimer RP. B-lymphocyte lineage cells and the
663 respiratory system. *J Allergy Clin Immunol.* 2013;131(4):933-57; quiz 58.
664 43. van Splunter M, van Hoffen E, Floris-Vollenbroek EG, Timmerman H, de Bos EL, Meijer
665 B, et al. Oral cholera vaccination promotes homing of IgA(+) memory B cells to the large
666 intestine and the respiratory tract. *Mucosal Immunol.* 2018;11(4):1254-64.
667 44. Clark SE, and Weiser JN. Microbial modulation of host immunity with the small molecule
668 phosphorylcholine. *Infect Immun.* 2013;81(2):392-401.
669 45. Lagergard T, and Branefors P. Nature of cross-reactivity between Haemophilus influenzae
670 types a and b and Streptococcus pneumoniae types 6A and 6B. *Acta Pathol Microbiol*
671 *Immunol Scand C.* 1983;91(6):371-6.
672 46. Kumar BV, Ma W, Miron M, Granot T, Guyer RS, Carpenter DJ, et al. Human Tissue-
673 Resident Memory T Cells Are Defined by Core Transcriptional and Functional Signatures in
674 Lymphoid and Mucosal Sites. *Cell Rep.* 2017;20(12):2921-34.
675 47. Trautmann A, Ruckert B, Schmid-Grendelmeier P, Niederer E, Brocker EB, Blaser K, et al.
676 Human CD8 T cells of the peripheral blood contain a low CD8 expressing cytotoxic/effector
677 subpopulation. *Immunology.* 2003;108(3):305-12.
678 48. Kaku Y, Imaoka H, Morimatsu Y, Komohara Y, Ohnishi K, Oda H, et al. Overexpression of
679 CD163, CD204 and CD206 on alveolar macrophages in the lungs of patients with severe
680 chronic obstructive pulmonary disease. *PLoS One.* 2014;9(1):e87400.
681 49. Yu YR, Hotten DF, Malakhau Y, Volker E, Ghio AJ, Noble PW, et al. Flow Cytometric
682 Analysis of Myeloid Cells in Human Blood, Bronchoalveolar Lavage, and Lung Tissues.
683 *Am J Respir Cell Mol Biol.* 2016;54(1):13-24.
684 50. Farina C, Theil D, Semlinger B, Hohlfeld R, and Meinl E. Distinct responses of monocytes
685 to Toll-like receptor ligands and inflammatory cytokines. *Int Immunol.* 2004;16(6):799-809.
686 51. Cosmi L, De Palma R, Santarlasci V, Maggi L, Capone M, Frosali F, et al. Human
687 interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor. *J Exp Med.*
688 2008;205(8):1903-16.

689 52. Kleinschek MA, Boniface K, Sadekova S, Grein J, Murphy EE, Turner SP, et al. Circulating
690 and gut-resident human Th17 cells express CD161 and promote intestinal inflammation. *J*
691 *Exp Med.* 2009;206(3):525-34.
692 53. Ballke C, Gran E, Baekkevold ES, and Jahnsen FL. Characterization of Regulatory T-Cell
693 Markers in CD4+ T Cells of the Upper Airway Mucosa. *PLoS One.* 2016;11(2):e0148826.
694 54. Overgaard NH, Jung JW, Steptoe RJ, and Wells JW. CD4+/CD8+ double-positive T cells:
695 more than just a developmental stage? *J Leukoc Biol.* 2015;97(1):31-8.
696 55. Cosmi L, Annunziato F, Galli MIG, Maggi RME, Nagata K, and Romagnani S. CRTH2 is
697 the most reliable marker for the detection of circulating human type 2 Th and type 2 T
698 cytotoxic cells in health and disease. *Eur J Immunol.* 2000;30(10):2972-9.
699 56. Dullforce P, Sutton DC, and Heath AW. Enhancement of T cell-independent immune
700 responses in vivo by CD40 antibodies. *Nat Med.* 1998;4(1):88-91.
701 57. Ohm-Laursen L, Meng H, Chen J, Zhou JQ, Corrigan CJ, Gould HJ, et al. Local Clonal
702 Diversification and Dissemination of B Lymphocytes in the Human Bronchial Mucosa.
703 *Front Immunol.* 2018;9:1976.
704 58. Lijek RS, and Weiser JN. Co-infection subverts mucosal immunity in the upper respiratory
705 tract. *Curr Opin Immunol.* 2012;24(4):417-23.
706 59. Hayashi EA, Akira S, and Nobrega A. Role of TLR in B cell development: signaling
707 through TLR4 promotes B cell maturation and is inhibited by TLR2. *J Immunol.*
708 2005;174(11):6639-47.
709 60. Vaughan AT, Gorringe A, Davenport V, Williams NA, and Heyderman RS. Absence of
710 mucosal immunity in the human upper respiratory tract to the commensal bacteria Neisseria
711 lactamica but not pathogenic Neisseria meningitidis during the peak age of nasopharyngeal
712 carriage. *J Immunol.* 2009;182(4):2231-40.
713 61. Vaughan AT, Brackenbury LS, Massari P, Davenport V, Gorringe A, Heyderman RS, et al.
714 Neisseria lactamica selectively induces mitogenic proliferation of the naive B cell pool via
715 cell surface Ig. *J Immunol.* 2010;185(6):3652-60.
716 62. Pizzolla A, Nguyen THO, Smith JM, Brooks AG, Kedzieska K, Heath WR, et al. Resident
717 memory CD8(+) T cells in the upper respiratory tract prevent pulmonary influenza virus
718 infection. *Sci Immunol.* 2017;2(12).
719 63. Weight CM, Venturini C, Pojar S, Jochems S, Reiné J, amp, et al. Epithelial control of
720 colonisation by Streptococcus pneumoniae at the human mucosal surface.
721 *bioRxiv.* 2018.
722 64. Ercoli G, Fernandes VE, Chung WY, Wanford JJ, Thomson S, Bayliss CD, et al.
723 Intracellular replication of Streptococcus pneumoniae inside splenic macrophages serves as
724 a reservoir for septicaemia. *Nat Microbiol.* 2018;3(5):600-10.
725 65. Mureithi MW, Finn A, Ota MO, Zhang Q, Davenport V, Mitchell TJ, et al. T cell memory
726 response to pneumococcal protein antigens in an area of high pneumococcal carriage and
727 disease. *The Journal of infectious diseases.* 2009;200(5):783-93.
728 66. Weber SE, Tian H, and Pirofski LA. CD8+ cells enhance resistance to pulmonary serotype 3
729 Streptococcus pneumoniae infection in mice. *J Immunol.* 2011;186(1):432-42.
730 67. Kurioka A, van Wilgenburg B, Javan RR, Hoyle R, van Tonder AJ, Harrold CL, et al.
731 Diverse Streptococcus pneumoniae Strains Drive a Mucosal-Associated Invariant T-Cell
732 Response Through Major Histocompatibility Complex class I-Related Molecule-Dependent
733 and Cytokine-Driven Pathways. *The Journal of infectious diseases.* 2018;217(6):988-99.
734 68. Wakao H, Sugimoto C, Kimura S, and Wakao R. Mucosal-Associated Invariant T Cells in
735 Regenerative Medicine. *Front Immunol.* 2017;8:1711.

736   69.   Serbina NV, Salazar-Mather TP, Biron CA, Kuziel WA, and Pamer EG. TNF/iNOS-
737   producing dendritic cells mediate innate immune defense against bacterial infection.
738   *Immunity*. 2003;19(1):59-70.
739   70.   Chen Z, Wang H, D'Souza C, Sun S, Kostenko L, Eckle SB, et al. Mucosal-associated
740   invariant T-cell activation and accumulation after in vivo infection depends on microbial
741   riboflavin synthesis and co-stimulatory signals. *Mucosal Immunol.* 2017;10(1):58-68.
742   71.   Howson LJ, Napolitani G, Shepherd D, Ghadbane H, Kurupati P, Preciado-Llanes L, et al.
743   MAIT cell clonal expansion and TCR repertoire shaping in human volunteers challenged
744   with Salmonella Paratyphi A. *Nat Commun.* 2018;9(1):253.
745   72.   Autengruber A, Gereke M, Hansen G, Hennig C, and Bruder D. Impact of enzymatic tissue
746   disintegration on the level of surface molecule expression and immune cell function. *Eur J*
747   *Microbiol Immunol (Bp).* 2012;2(2):112-20.
748   73.   Pongracz J, Webb P, Wang K, Deacon E, Lunn OJ, and Lord JM. Spontaneous neutrophil
749   apoptosis involves caspase 3-mediated activation of protein kinase C-delta. *J Biol Chem.*
750   1999;274(52):37329-34.
751   74.   Goodyear AW, Kumar A, Dow S, and Ryan EP. Optimization of murine small intestine
752   leukocyte isolation for global immune phenotype analysis. *J Immunol Methods.*
753   2014;405:97-108.
754   75.   Gritzfeld JF, Wright AD, Collins AM, Pennington SH, Wright AK, Kadioglu A, et al.
755   Experimental human pneumococcal carriage. *J Vis Exp.* 2013(72).
756   76.   Zunder ER, Finck R, Behbehani GK, Amir el AD, Krishnaswamy S, Gonzalez VD, et al.
757   Palladium-based mass tag cell barcoding with a doublet-filtering scheme and single-cell
758   deconvolution algorithm. *Nat Protoc.* 2015;10(2):316-33.
759   77.   Durrenberger PF, Ettorre A, Kamel F, Webb LV, Sim M, Nicholas RS, et al. Innate
760   immunity in multiple sclerosis white matter lesions: expression of natural cytotoxicity
761   triggering receptor 1 (NCR1). *J Neuroinflammation.* 2012;9:1.
762   78.   Krzywinski M, Schein J, Birol I, Connors J, Gascoyne R, Horsman D, et al. Circos: an
763   information aesthetic for comparative genomics. *Genome Res.* 2009;19(9):1639-45.

764

765

Figure and figure legends

Figure 1. Mass cytometry from nasal biopsies following experimental human pneumococcal challenge. A) Study design showing pneumococcal inoculation (green bar) and sample collection.

Subjects who acquired pneumococcus following challenge are depicted in red (n=8), while those protected are depicted in blue (n=12). Antibiotics (abx) were administered in the 3 days leading up to biopsy collection (blue area). B) Viable cell yield following enzymatic biopsy digestion for the twenty biopsies collected for CyTOF. Individual samples and boxplots, depicting median and interquartile ranges, with whiskers extending to 1.5× interquartile range or maximum value, are shown. C) Circle diagram showing all 293 defined clusters within 9 lineages and 22 subpopulations. From outside in: number of cells in each cluster is depicted by grey bars. Relative expression for 36 markers is shown with red depicting higher expression (CD45 and Epcam are not depicted). Association with carriage state is shown, where blue bars depict the fold-change of the median of normalized abundance in carriage$^-$ subjects over carriage$^+$ subjects (Mann-Whitney test, $p < 0.05$ shown only). Significant correlations between Spn density at either day 2 or day 7 with normalized abundance are depicted by circles, with red indicating a negative association. Spearman correlation analyses were performed with all subjects where carriage$^-$ subjects were included with a density of 0. Ribbons connect highly correlated (r>0.70) clusters that were associated with Spn carriage status not belonging to the same lineage, with colour indicating the lineage of origin. DN_T = double negative T cells, Gran = granulocytes, ILC = innate lymphoid cells.

Figure 2. CyTOF analysis strategy. A) CyTOF data files were pre-gated using Flowjo to identify cells

(DNA$^+$ Bead$^-$), followed by selecting viable immune cells (CD45$^+$ Dead$^-$). These cells were exported

and loaded in Cytosplore for hierarchical stochastic neighbour embedding (h-sne), in which lineages, subpopulations and clusters were sequentially identified in three steps. Gating for naïve CD4$^+$ T cells is shown as an example. B) Cells were clustered using all 38 markers minus the epithelial marker Epcam and lineages were then defined based on the expression of nine markers. Clustered lineages and expression of included markers are shown. Subpopulations for C) CD8$^+$ T cells, D) granulocytes, E) CD4$^+$ T cells, F) innate lymphoid cells, G) CD117$^+$ cells and H) double-negative T cells were defined based on the expression of the depicted markers. B cells, plasma cells, myeloid cells were not further divided into subpopulations due to lack of clear clustering by relevant markers. Cell subpopulations were then further divided into clusters using all 38 markers minus the epithelial marker Epcam.

Figure 3. Nasal B cells are depleted following pneumococcal carriage. A) Heatmap showing the
expression of thirty-seven markers for all B cell clusters. Clusters were ordered based on similarity

and a distance dendrogram is depicted. B) The relative abundance for each of the three significantly higher clusters normalized to stromal cells is expressed on a $\log_{10}$ scale for carriage⁻ (Spn–, blue, n=12) and carriage⁺ (Spn+, red, n=8) subjects. Boxplots, depicting median and interquartile ranges, with whiskers extending to 1.5× interquartile range or maximum value, and individual subjects are shown. C) Levels of CD19⁺ nasal B cells longitudinally measured by flow cytometry from minimally-invasive nasal curettes in an independent cohort for carriage⁻ (Spn–, blue, n=52) and carriage⁺ (Spn+, red, n= 42) subjects. Mean and standard error of mean of log2-transformed fold change levels to baseline are shown. * $p < 0.05$ by Wilcoxon test comparing to baseline with Bonferroni correction for comparing multiple timepoints.

Figure 4. Pneumococcal carriage leads to increased systemic plasmablasts. A) Levels of 6B polysaccharide-specific, 15B polysaccharide-specific, Pneumolysin derivative b (Pneumolysin)-specific or all plasmablast amongst total B cells were measured from PBMC collected at baseline (Day -5) and at the time of biopsy (Day 10 post inoculation). Boxplots depicting median and interquartile ranges, with whiskers extending to 1.5× interquartile range or maximum value, and individual subjects are shown with carriage⁻ in blue (n=12) and carriage⁺ in red (n=8). Paired samples are connected by dashed lines. * p < 0.05, ** p < 0.01 by Wilcoxon test comparing a group to its baseline. B) Levels of CCR10⁺ plasmablasts for 6B-specific and total plasmablasts measured from PBMC collected at baseline (Day -5) and at the time of biopsy (Day 10 post inoculation). Boxplots and individual subjects are depicted with carriage⁻ in blue and carriage⁺ in red with paired

samples connected by dashed lines. ** p < 0.01 by Wilcoxon test comparing a group to its baseline.

C) Correlations between fold-change in levels of 6B PS-specific and total plasmablasts between baseline and day 10 against levels of B cell clusters measured by CyTOF. Color and size of symbols reflect the Spearman rho value. * p < 0.05 and ** p < 0.01 by Spearman test.

Figure 5. Increased MAIT responses associate with protection from carriage. A) Heatmap showing the expression of thirty-seven markers for each of the four CD8$^+$ clusters that were significantly different between carriers and non-carriers. Non-significant CD8$^+$ T clusters are not shown. Below the heatmap, the abundance for each of the significantly higher clusters normalized to stromal cells is expressed on a log$_{10}$ scale for carriage$^-$ (blue) and carriage$^+$ (red) subjects. Boxplots depicting median and interquartile ranges, with whiskers extending to 1.5× interquartile range or maximum value, and individual subjects are depicted. B) Representative flow cytometry contour plot of CD8$^+$ CD69$^+$ and CD8$^+$ CD69$^-$ T cells, showing CD103 and CD49a tissue resident marker expression on nasal biopsy cells (n=4). C) Representative flow cytometry contour plot of unstimulated nasal biopsy cells, and nasal biopsy cells and PBMC stimulated overnight with PMA and ionomycin (PI) to assess functional capacity (n=4). D) TNF, IFN-ɣ and IL-17A production by CD8$^+$ MAIT cells (CD161$^+$TCRvα7.2$^+$) after 3-day in vitro stimulation with heat-inactivated pneumococcus (HI-Spn) or left unstimulated for carriage$^-$ (blue, n=14) and carriage+ (red, n=8) subjects in PBMC collected at baseline. Boxplots and individual subjects, connected by dashed lines, are shown. ** $p < 0.01$ by Wilcoxon test, *** $p < 0.001$ by Wilcoxon test. E) Correlations between the difference in cytokine production (total of TNF and IFN-ɣ) by MAIT cells in vitro stimulated with HI-Spn or left unstimulated against CD8$^+$ CD161$^+$ T cell clusters measured by CyTOF (n=20). Colour and size of symbols reflect the Spearman rho value. * $p < 0.05$ by Spearman test.

Figure 6. Association between baseline IgG against Spn and cluster abundance. A) Levels of baseline IgG levels against whole cell 6B Spn in serum are shown carriage⁻ (blue, n=12) and carriage+ (red, n=8) subjects. Boxplots depicting median and interquartile ranges, with whiskers extending to 1.5× interquartile range or maximum value, and individual subjects, connected by dashed lines, are shown. B) Correlation between abundance of clusters and baseline levels of IgG are shown. Individuals subjects and regression lines per group are shown, with 95% confidence intervals depicted in grey. *p=0.03 determined by linear model including carriage status and log-transformed baseline IgG levels.

A H&E

Epithelium

Red blood cells

Submucosal glands

B Negative control

C CD3 (T cells)

40x

D CD4 (T cells)

40x

E CD8 (T cells)

40x

F CD161 (MAIT cells)

40x

G CD20 (B cells)

40x

H CD68 (Myeloid cells)

40x

I CD66b (Granulocytes)

40x

**J** CD11b (Granulocytes and others)

40x

Figure 7. Immunohistochemistry on serial sections of a nasal biopsy. To establish an overall cellular distribution in the tissue a 10x magnification is shown for each of the markers. A 40x inset is also included to visualize some individual positive cells. A) Haematoxylin and eosin staining showing the entire biopsy. Staining of subsequent slices showing the biopsy at the epithelial edge for the markers B) negative control, C) CD3, D) CD4, E) CD8, F) CD161, G) CD20, H) CD68, I) CD66b and J) CD11b. A scale showing 250μm are added to all panels and a 40x inset is included. Slices were counterstained with haematoxylin and eosin. Some background staining of the extracellular matrix is present for CD161 (panel F). Biopsy was derived from one challenged, carriage$^-$ subject.

Tables

Table 1. Volunteer cohort characteristics divided by carriage state.

	Carriage⁻ (n=12)	Carriage⁺ (n=8)
Female gender (%)	4 (33.3%)	4 (50%)
Median age (min-max)	21 (18-44)	23 (20-30)
Median day 2 Spn density CFU/mL (min-max)	-	127.2 (5.8 - 38677.7)
Median day 7 Spn density CFU/mL (min-max)	-	187.5 (0 – 21736.6)

Table 2. List of lineages and subpopulations derived from nasal biopsy analysis. For all nine lineages and twenty-two subpopulations, the numbers of defined cell clusters are shown. In addition, the total numbers of cells within those lineages/subpopulations and the percentage of that subpopulation within all cells for carriage⁻ and carriage⁺ subjects are shown. Memory cells are defined as CD45RO⁺RA⁻ and naïve cells are defined as CD45RO⁻RA⁺

Lineage	Subpopulation	Clusters	Cells	%Carriage⁻	%Carriage+
CD8⁺ T cells	CD161⁺ CD8⁺ T cells	17	25103	13.0	11.7
	Naive CD8⁺ T cells	20	9042	3.8	6.3
	Memory CD8⁺ T cells	26	36860	18.1	19.4
	Total	**63**	**71005**	**34.9**	**37.3**
CD4⁺ T cells	CD161⁺ CD4⁺ T cells	21	36328	18.7	17.0
	CD25ʰⁱ CD4⁺ T cells	9	2743	1.2	1.9
	Naïve CD4⁺ T cells	9	4235	2.2	1.8
	Memory CD4⁺ T cells	23	21158	10.5	10.8
	CD45RO⁻RA⁻ CD4⁺ T	6	2743	1.2	1.9
	Total	**68**	**67207**	**33.8**	**33.5**
Myeloid cells	-	25	15226	7.4	8.3
Innate lymphoid cells	CD8⁻CD16⁺ ILC	13	3683	2.0	1.5
	CD8⁺CD16⁺ ILC	5	2392	1.1	1.4
	CD16⁻CD127⁺ ILC	4	1550	0.8	0.6
	CD16⁻CD127⁻ ILC	9	3417	1.7	1.8
	Total	**31**	**11042**	**5.6**	**5.3**
B cells	-	22	10279	5.8	3.7
CD4⁻CD8⁻ T cells	TCRgd T cells	9	1838	0.8	1.2
	DN T cells	7	3052	1.6	1.5
	CD8ᵈⁱᵐ T cells	13	4317	2.2	2.1
	Total	**29**	**9207**	**4.6**	**4.7**

Granulocytes	CD66b$^+$ Granulocytes	19	5478	2.9	2.4
	CD66b$^-$ Granulocytes	2	662	0.3	0.3
	Total	**21**	**6140**	**3.2**	**2.7**
CD117$^+$ cells	CD117$^+$ lymphocytes	8	2566	1.3	1.3
	CD117$^+$ mast cells	13	2810	1.5	1.2
	Total	**21**	**5376**	**8.5**	**6.2**
Plasma cells	-	13	3944	2.0	2.0
9	**22**	**293**	**199426**	**100**	**100**